X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.fiercebiotech.com/biotech/ultimovacs-lays-40-survive-wake-cancer-vaccines-phase-2-fail
https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-liver-cancer-treatment-meets-main-goal-late-stage-study-2024-03-20/
https://www.globenewswire.com//news-release/2024/03/07/2841921/0/en/Ultimovacs-Announces-Topline-Results-from-INITIUM-Study-Evaluating-UV1-Vaccination-Added-to-Ipilimumab-and-Nivolumab-in-Patients-with-Unresectable-or-Metastatic-Malignant-Melanoma.html
https://www.fiercepharma.com/pharma/bms-shows-success-opdivo-yervoy-combo-first-line-colorectal-cancer
https://www.onclive.com/view/neoadjuvant-nivolumab-ipilimumab-combo-elicits-responses-safety-in-resectable-hcc
https://www.fiercepharma.com/pharma/bristol-myers-astrazeneca-settle-pd-1-ctla-4-cancer-immunotherapy-patent-suits-510m
https://www.fiercepharma.com/pharma/regenerons-libtayo-chalks-new-lung-cancer-win-alongside-bristols-yervoy-it-doesnt-matter
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377
https://www.prnewswire.com/news-releases/intensity-therapeutics-reports-use-of-int230-6-alone-or-in-combination-with-ipilimumab-shows-evidence-of-direct-tumor-necrosis-and-promising-overall-survival-results-in-adult-subjects-with-metastatic-sarcomas-at-the-connective-tis-301682483.html
http://www.pharmafile.com/news/734372/nice-issues-positive-appraisal-document-combination-treatment-advanced-kidney-cancer
https://endpts.com/bristol-myers-combo-hits-a-roadblock-in-phiii-kidney-test-as-the-search-to-rival-keytruda-continues/
http://www.pharmafile.com/news/678897/first-immunotherapy-untreated-unresectable-malignant-pleural-mesothelioma-recommended-ni
https://www.fiercepharma.com/pharma/exelixis-trot-out-opdivo-yervoy-cabometyx-combo-win-kidney-cancer-will-fda-accept
https://www.fiercepharma.com/marketing/bristol-myers-opdivo-fights-keytruda-again-dual-fda-nods-esophageal-cancer
https://seekingalpha.com/news/3839084-bristol-myers-opdivoyervoy-combo-fails-to-improve-overall-survival-in-certain-bladder-cancer-patients-in-trial
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377
http://www.pharmafile.com/news/605591/nice-recommends-new-combination-untreated-advanced-kidney-cancer
https://www.globenewswire.com/news-release/2021/12/27/2358037/10391/en/TRACON-Pharmaceuticals-Announces-Positive-Results-from-the-Independent-Data-Monitoring-Committee-Review-of-Interim-Safety-and-Efficacy-Data-from-the-Ongoing-ENVASARC-Pivotal-Trial.html
https://www.globenewswire.com/news-release/2021/10/25/2319675/0/en/TCR-Therapeutics-Announces-Clinical-Trial-Collaboration-Agreement-with-Bristol-Myers-Squibb-to-Evaluate-Gavo-cel-in-Combination-with-Opdivo-and-Yervoy-in-Mesothelin-Expressing-Soli.html
https://www.fiercepharma.com/marketing/bms-and-gryt-health-push-for-diversity-oncology-new-initiative
https://beyondspringpharma.com/beyondspring-announces-first-patient-treated-in-phase-2-study-with-plinabulin-combined-with-nivolumab-ipilimumab-in-patients-in-3rd-line-recurrent-small-cell-lung-cancer-patients-who-failed-checkpoi/?utm_source=rss&utm_medium=rss&utm_campaign=beyondspring-announces-first-patient-treated-in-phase-2-study-with-plinabulin-combined-with-nivolumab-ipilimumab-in-patients-in-3rd-line-recurrent-small-cell-lung-cancer-patients-who-failed-checkpoi
https://www.fiercepharma.com/pharma/newly-diagnosed-stomach-cancer-2-opdivo-yervoy-flops-show-immunotherapy-alone-might-not-be
https://www.globenewswire.com/news-release/2021/09/17/2298997/0/en/Gritstone-Announces-Dosing-of-First-Solid-Tumor-Patient-with-Optimized-SLATE-Off-the-Shelf-Mutant-KRAS-directed-Neoantigen-Immunotherapy-in-Phase-2-Clinical-Trial.html
https://www.globenewswire.com/news-release/2021/09/17/2298996/0/en/Gritstone-Announces-Positive-Clinical-Data-with-GRANITE-Individualized-Neoantigen-Immunotherapy-Program-during-ESMO-2021-and-Launch-of-Randomized-Clinical-Trial-Program-in-Colorect.html
https://www.clinicaltrialsarena.com/news/bms-opdivo-mesothelioma-trial/
https://www.ono-pharma.com/sites/default/files/en/news/press/enews20210914_0.pdf
https://www.onclive.com/view/nivolumab-ipilimumab-approved-in-europe-for-dmmr-or-msi-h-metastatic-colorectal-cancer
https://www.prnewswire.com/news-releases/immunogenesis-announces-publication-of-phase-1-data-on-its-hypoxia-reversal-agent-highlighting-efficacy-and-genetic-expression-correlatives-in-advanced-cancer-301313485.html
https://www.businesswire.com/news/home/20210607005568/en/Osel-Announces-Positive-Results-from-Phase-1b-Trial-of-Live-Biotherapeutic-Product-CBM588-in-Combination-with-Checkpoint-Inhibitor-CPI-Therapy-in-Metastatic-Renal-Cell-Carcinoma
https://www.globenewswire.com/news-release/2021/06/07/2242678/32478/en/Final-Data-from-Calithera-Biosciences-Phase-2-CANTATA-Study-in-Renal-Cell-Carcinoma-Presented-at-2021-ASCO-Annual-Meeting.html
https://endpts.com/asco21-bristol-myers-solo-dual-i-o-regimens-best-chemo-alone-with-one-exception-in-first-line-esophageal-patients/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377
http://www.pharmatimes.com/news/nice_no_for_opdivoyervoy_lung_cancer_combo_1366600
https://www.fiercebiotech.com/biotech/xilio-raises-95m-to-take-twists-yervoy-and-il-2-into-clinic
Market Place
Share 
